Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors: Ivanova, Vera; Garbuzenko, Olga B; Reuhl, Kenneth R; Reimer, David C; Pozharov, Vitaly P; Minko, Tamara

Published In Eur J Pharm Biopharm, (2013 Jun)

Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal form of interstitial lung disease. We hypothesized that the local pulmonary delivery of prostaglandin E2 (PGE2) by liposomes can be used for the effective treatment of IPF. To test this hypothesis, we used a murine model of bleomycin-induced IPF to evaluate liposomal delivery of PGE2 topically to the lungs. Animal survival, body weight, hydroxyproline content in the lungs, lung histology, mRNA, and protein expression were studied. After inhalation delivery, liposomes accumulated predominately in the lungs. In contrast, intravenous administration led to the accumulation of liposomes mainly in kidney, liver, and spleen. Liposomal PGE2 prevented the disturbances in the expression of many genes associated with the development of IPF, substantially restricted inflammation and fibrotic injury in the lung tissues, prevented decrease in body weight, limited hydroxyproline accumulation in the lungs, and virtually eliminated mortality of animals after intratracheal instillation of bleomycin. In summary, our data provide evidence that pulmonary fibrosis can be effectively treated by the inhalation administration of liposomal form of PGE2 into the lungs. The results of the present investigations make the liposomal form of PGE2 an attractive drug for the effective inhalation treatment of idiopathic pulmonary fibrosis.

PubMed ID: 23228437 Exiting the NIEHS site

MeSH Terms: Administration, Intravenous; Animals; Bleomycin/toxicity; Body Weight/drug effects; Dinoprostone/administration & dosage*; Disease Models, Animal; Hydroxyproline/metabolism; Idiopathic Pulmonary Fibrosis/chemically induced; Idiopathic Pulmonary Fibrosis/drug therapy*; Immunohistochemistry; Kidney/drug effects; Liposomes/administration & dosage; Liposomes/metabolism; Liver/drug effects; Lung/drug effects; Lung/metabolism; Mice; RNA, Messenger/metabolism; Spleen/drug effects; Time Factors; Tissue Distribution

Back
to Top